Contact Us

Resources

Bora Pharmaceuticals is Awarded Outstanding Company of the Year at Bio-Asia Taiwan 2023

Bora Pharmaceuticals is Awarded Outstanding Company of the Year at Bio-Asia Taiwan 2023

Bora has been awarded "Outstanding Company of the Year" by an independent panel of international judges during Bio-Asia Taiwan exhibit taking place in Taipei, Taiwan July 24-26, 2023. Bora was chosen from a short list of several candidates for its demonstrated leadership in the Taiwan Biopharma industry. Bobby Sheng said; "Our team's focused dedication to excellence in quality and customer...

read more
Bora Pharmaceuticals Featured in Contract Pharma – What are 3 Key Trends shaping the CDMO industry in 2023 and beyond?

Bora Pharmaceuticals Featured in Contract Pharma – What are 3 Key Trends shaping the CDMO industry in 2023 and beyond?

,

Read Contract Pharma - "What are 3 Key Trends shaping the CDMO industry in 2023 and beyond?" Published on June 22, 2023 Bobby Sheng sheds some light on the three main trends impacting CDMOs in 2023 - and potentially for many years ahead. One such trend is an increased demand for the production of novel biologics. The rising need for biologics means more pressure on the industry to bring these...

read more
Bora Pharmaceuticals and Celltrion Partners to Expand OSD capabilities in APAC market

Bora Pharmaceuticals and Celltrion Partners to Expand OSD capabilities in APAC market

Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) and Celltrion Asia Pacific Pte., Ltd. (“Celltrion”), a subsidiary of Celltrion Group Inc, have today announced their partnership to contract manufacture and commercialize a range of oral dosage form drugs (OSD) across the APAC region. The range of oral dosage form products will be manufactured at Bora’s Zhunan Site, which is one of the...

read more